psoriasis
Janssen’s Tremfya gets go-ahead from NICE in plaque psoriasis
May 11, 2018Medical Communications, Sales and Marketing Janssen, NICE, Tremfya, UK, pharma, psoriasis
NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the …
Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis
February 19, 2018Research and Development, Sales and Marketing Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis
Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …
Vanilla compound found to prevent psoriasis
December 5, 2017Manufacturing and Production, Research and Development biotech, drugs, pharma, pharmaceutical, psoriasis, vanilla
Psoriasis is a big pharmaceutical market, it’s the most common autoimmune disease in the US and as many as 7.5 …
Novartis reveals strong long-term data Cosentyx in psoriasis of the hands and feet
December 1, 2017Medical Communications, Research and Development Cosentyx, Novartis, palmoplantar psoriasis, pharma, psoriasis
Novartis has released new data for Consentyx (secukinumab) which it claims make the IL-17A inhibitor “the first biologic to show …
Psoriasis patients at greater risk of type 2 diabetes, study reveals
November 15, 2017Research and Development diabetes, pharma, psoriasis, type 2 diabetes
Researchers at the University of Pennsylvania’s Perelman School of Medicine have discovered that people with psoriasis are more at risk …
FDA expands Janssen’s Stelara to cover adolescent psoriasis patients
October 16, 2017Sales and Marketing FDA, Janssen, Stelara, pharma, psoriasis
Janssen has announced that the FDA has approved an expanded indication for its psoriasis therapy Stelara (ustekinumab) for the treatment …
Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance
September 13, 2017Research and Development Cosentyx, Novartis, pharma, pharmaceutical, psoriasis
At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx …
NICE recommends plaque psoriasis contender for NHS use
August 8, 2017Manufacturing and Production, Sales and Marketing Almirall, NICE< Skilarence, drugs, life sciences, medicine, pharma, pharmaceuticals, plaque psoriasis, psoriasis
The use of Almirall’s psoriasis drug Skilarence (dimethyl fumarate) on the UK’s NHS is one step closer after NICE gave …
Top Ten most popular articles on Pharmafile.com this week
July 21, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Teva, biotech, brexit, drugs, healthcare, pharma, pharmaceutical, psoriasis, top ten
The week was characterised by two big psoriasis approval stories, while Amgen’s osteoporosis treatment was knocked back. Novartis CEO Joe …
Leo Pharma gets European approval for unique plaque psoriasis drug
July 20, 2017Sales and Marketing EU, European Commission, biotech, drugs, pharma, pharmaceutical, psoriasis
The European Commission has announced that it has decided to approve Leo Pharma’s Kyntheum (brodalumab), making it the first and …
Psoriasis drug Siliq will be cheapest in class, Valeant reveals
April 24, 2017Sales and Marketing Siliq, Valeant, psoriasis
Canadian pharmaceutical firm Valeant has announced the list price for its psoriasis treat Siliq (brodalumab) will stand at $3,500 a …
Novartis’ psoriasis drug allows some patients to go into remission
March 21, 2017Research and Development Cosentyx, Novartis, psoriasis
Novartis released data on patient’s reaction to Cosentyx for the treatment of psoriasis, finding that as many as 21% of …
Phase 3 data for Janssen psoriasis drug shows efficacy over Humira
March 6, 2017Research and Development, Sales and Marketing Humira, Janssen, guselkumab, psoriasis
Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate …
FDA approves Valeant plaque psoriasis drug despite suicide concerns
February 16, 2017Sales and Marketing FDA, Siliq, Valeant, psoriasis
The US Food and Drug Administration (FDA) has announced that it has approved Valeant Pharmaceutical’s injectable psoriasis treatment Siliq (brodalumab) …
FDA approves first therapy for paediatric psoriasis treatment
November 7, 2016Sales and Marketing Amgen, Enbrel, paediatric, psoriasis
Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
